By Nainesh Shah, Senior Project Engineer, Asahi Kasei Bioprocess America
Generating a consistent, optimized buffer solution for a drug product is crucial to ensuring its efficacy and establishing a reliable supply chain for market scale-up. Because of their varying applications and formulations, finding the right solution to guarantee a buffer that meets a project’s needs at every phase is crucial.
Many pharmaceutical companies arrive at the buffer formulation stage and immediately begin the process of partnering with an outside organization to produce their buffers. While this represents a perfectly valid choice in many instances, there are a number of scenarios in which opting for in-house buffer production affords companies greater flexibility, tighter turnaround, and more freedom than most contract organizations can offer.
MOTIV™, the award-winning Inline Buffer Formulation (IBF) fluid management systems from Asahi Kasei Bioprocess America (AKBA), represent some of the most advanced equipment for buffer formulation available. By providing technologies that offer customers greater productivity, heightened control, and tighter timelines, AKBA helps companies increase their downstream production efficiency and manage risk more effectively than ever before.